Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | The mechanism of action of hydroxyurea in SCD

Andreas Kulozik • 24 Apr 2022
The 2022 Tandem Meetings
Non-Malignant Sickle Cell Disease Hydroxyurea

Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, describes the different mechanisms of action of hydroxyurea in the treatment of sickle cell disease (SCD). Hydroxyurea induces hemoglobin F and affects the adherence of cells to the endothelium of blood vessels, which helps to reduce the incidence of vaso-occlusive crises and other complications of SCD. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Andreas Kulozik

1:01
Management of patients with thalassemia who cannot undergo HSCT or gene therapy
Andreas Kulozik • 24 Apr 2022
2:13
The pathophysiology of β-thalassemia
Andreas Kulozik • 24 Apr 2022
1:48
Toxicity of beti-cel in transfusion-dependent β-thalassemia
Andreas Kulozik • 24 Apr 2022
2:13
Recent advances in β-thalassemia
Andreas Kulozik • 24 Apr 2022

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals